Karolinska Development: Lipidor and Cadila Pharmaceuticals agree on Phase III study and sale of Psoriasis product
Wednesday, June 01, 2016
Karolinska Development AB : Lipidor and Cadila Pharmaceuticals announce agreement on Phase III clinical study and joint commercialization of topical Psoriasis product.
Lipidor and Cadila Pharmaceuticals have entered into collaboration agreement on commercialization of sprayable anti-psoriatic product consisting of generic Vitamin D analogue, Calcipotriol, formulated with Lipidors patented lipid-based drug delivery technology, AKVANO.
Product targets patients with mild to moderate psoriasis.
Under collaboration agreement, Cadila Pharmaceuticals will conduct a Phase III program in India starting in 2016.
Source : reuters.com
